In July 2022, Innoviva announced its acquisition of La Jolla Pharmaceuticals Company in a deal with an implied enterprise value of approximately $149 million.

This acquisition strengthened Innoviva’s portfolio in infectious diseases, anchored by the company’s purchase of Entasis Therapeutics Holdings, an advanced late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products.